MITCHELL GOLD - 28 Dec 2023 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.

Role
Executive Chairman and CEO, Director
Signature
/s/ Mitchell Gold
Issuer symbol
N/A
Transactions as of
28 Dec 2023
Net transactions value
-$19,711
Form type
4
Filing time
29 Dec 2023, 19:32:15 UTC
Previous filing
27 Dec 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Options Exercise $660 +1,016 $0.6500* 1,016 28 Dec 2023 Direct F1
transaction ALPN Common Stock Sale $20,362 -1,016 -100% $20.04 0 28 Dec 2023 Direct F1, F2
transaction ALPN Common Stock Options Exercise $948,378 +74,441 +2.9% $12.74 2,675,421 28 Dec 2023 Alpine ImmunoSciences, L.P. F3, F4
transaction ALPN Common Stock Tax liability $948,388 -48,264 -1.8% $19.65 2,627,157 28 Dec 2023 Alpine ImmunoSciences, L.P. F3, F4, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -1,016 -0.41% $0.000000 247,951 28 Dec 2023 Common Stock 1,016 $0.6500 Direct F1, F7
transaction ALPN Warrant (right to buy) Options Exercise $0 -74,441 -100% $0.000000* 0 28 Dec 2023 Common Stock 74,441 $12.74 Alpine ImmunoSciences, L.P. F3, F4, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $20.00 to $20.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
F4 The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F5 On December 28, 2023, the warrant reported herein was net exercised in full for $12.74 per share, resulting in Issuer's withholding of 48,264 shares to pay the exercise price and issuing to the reporting person the remaining 26,177 shares
F6 Represents the average closing price of Issuer's common stock for the five consecutive trading days ending on December 27, 2023 (the date immediately preceding the warrant exercise date).
F7 100% of the shares underlying the option were fully vested as of January 20, 2021.
F8 Pursuant to the terms of a Securities Purchase Agreement, dated January 15, 2019 by and among the Issuer and the Purchasers set forth on the signature pages thereto, holder purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock.